Overview
- The two studies published Sept. 3–5, 2026 include an NYU-led genetic analysis that used 22 GLP1R gene variants as proxies and found a roughly 7% added risk of male-pattern hair loss tied to higher GLP-1 receptor activity.
- A University of Pennsylvania electronic health record study examined about 50,000 adults with type 2 diabetes and reported that GLP-1 users were 37% more likely to have documented hair-loss than patients on SGLT2 inhibitors and 68% more likely than those on DPP4 inhibitors.
- Both teams stress limits: the genetic study used Mendelian randomization instead of measuring drug exposure, and both analyses drew mainly on White cohorts and male-focused measures, so the findings may not generalize to women or broader populations.
- Researchers caution the effect sizes are modest, that rapid weight loss (telogen effluvium) remains a plausible non-drug explanation, and that the clinical importance is uncertain pending mechanistic and prospective studies.
- Authors propose next steps that include lab work on how GLP-1 affects hair follicles, larger diverse trials, and exploration of pre-prescription risk screening or preventive treatments such as topical minoxidil, while regulators have not listed hair loss as an official GLP-1 side effect.